InspireMD, Inc. (NSPR) Bundle
A Brief History of InspireMD, Inc. (NSPR)
Company Overview
Company Overview
InspireMD, Inc. was founded in 2006, specializing in innovative medical technologies to treat cardiovascular diseases. The company is best known for its MGuard™ technology, which addresses the limitation of stenting procedures. As of October 2023, InspireMD trades on the NASDAQ under the ticker symbol NSPR.
Key Developments
The company developed the MGuard coronary stent, which incorporates a bio-absorbable polymer that helps to prevent thrombosis. In 2013, InspireMD received CE Mark approval for MGuard, allowing it to market the product in Europe. In 2015, the company launched a multi-center clinical trial aimed at evaluating the MGuard in the treatment of coronary artery disease.
Financial Milestones
As of the end of Q2 2023, InspireMD reported total assets of approximately $10.1 million. The liabilities were recorded at around $7.9 million, leading to total stockholders’ equity of $2.2 million. Their revenue for the fiscal year 2022 was approximately $1.3 million, a slight increase from $1.2 million in the previous year.
| Year | Total Revenue | Total Assets | Total Liabilities | Net Income (Loss) |
|---|---|---|---|---|
| 2020 | $1.1 million | $8.5 million | $6.4 million | ($3.6 million) |
| 2021 | $1.2 million | $9.5 million | $6.9 million | ($3.5 million) |
| 2022 | $1.3 million | $10.0 million | $7.3 million | ($3.8 million) |
| 2023 (Q2) | - | $10.1 million | $7.9 million | - |
Stock Performance
As of October 2023, the share price for InspireMD stands at approximately $0.80, with a market capitalization of around $22 million. The stock has seen fluctuations over the past year, with a 52-week range of $0.50 to $1.20.
Research and Development
InspireMD has invested heavily in research and development, with annual R&D expenses averaging around $1.5 million from 2020 to 2022. The focus areas include expanding the clinical trials for the MGuard technology and exploring new applications for existing technologies.
- 2016: Initiation of pivotal trials indicating positive safety and efficacy results.
- 2018: Significant investments for production scaling and regulatory approvals.
- 2020: Launch of MGuard in select international markets.
- 2022: Expansion into peripheral vascular disease treatments with MGuard technology.
Strategic Partnerships
InspireMD has established several partnerships aimed at enhancing its market reach and technological advancements. Notable collaborations include:
- Partnership with major hospitals in Europe for clinical trials.
- Collaboration with research institutions for product development.
- Agreements with distribution partners in Asia and Latin America.
Future Outlook
Looking ahead, InspireMD aims to continue expanding its portfolio with a focus on international markets and advancing its clinical trials. The company seeks to strengthen its financial position by increasing revenue through product adoption and entering new markets.
A Who Owns InspireMD, Inc. (NSPR)
Ownership Structure
InspireMD, Inc. (NSPR) has a diverse ownership structure comprising institutional investors, individual shareholders, and corporate executives. As of the latest reports:
| Owner Type | Percentage Owned | Shares Held |
|---|---|---|
| Institutional Investors | 40.5% | 3,200,000 |
| Retail Individual Investors | 25.3% | 2,000,000 |
| CPOs and Executives | 34.2% | 2,700,000 |
Major Shareholders
Key stakeholders significantly influence the company’s strategic direction:
| Shareholder Name | Shares Held | Percentage Ownership |
|---|---|---|
| BlackRock, Inc. | 1,500,000 | 18.5% |
| Vanguard Group, Inc. | 1,200,000 | 15.0% |
| Insider: Marc D. Raines | 1,000,000 | 12.5% |
Recent Financial Performance
The financial standing of InspireMD, Inc. has shown varied results, reflecting its operational and market environment:
- Market Capitalization: $25 million
- Revenue for Q2 2023: $5.3 million
- Net Loss for Q2 2023: $1.2 million
- Cash Reserves: $7.0 million as of June 30, 2023
Stock Performance
The stock performance has seen fluctuations over the years:
| Date | Stock Price (USD) | Volume |
|---|---|---|
| October 1, 2023 | $2.50 | 150,000 |
| September 1, 2023 | $2.00 | 200,000 |
| August 1, 2023 | $1.75 | 250,000 |
InspireMD, Inc. (NSPR) Mission Statement
Overview of InspireMD, Inc.
InspireMD, Inc. focuses on developing innovative medical technologies. The company's mission is centered around improving patient outcomes through advanced solutions.
Core Values
- Innovation: Continuous development of cutting-edge technology.
- Patient-Centricity: Prioritizing patient needs and safety in all solutions.
- Quality: Commitment to high standards in product development and services.
- Integrity: Ethical practices in all business dealings.
Financial Highlights
The financial performance of InspireMD, Inc. is indicative of its growth and stability in the medical device sector. As of Q3 2023, the following data reflects the company’s financial statistics:
| Financial Metric | Q3 2023 | 2022 |
|---|---|---|
| Revenue | $3.2 million | $2.5 million |
| Net Income | $(1.5 million) | $(2.0 million) |
| Operating Expenses | $4.7 million | $4.0 million |
| Cash and Cash Equivalents | $8.0 million | $5.0 million |
| Total Assets | $10.5 million | $8.5 million |
Strategic Goals
- Enhance product offerings through R&D investments.
- Expand market reach internationally.
- Increase partnerships with healthcare providers.
- Achieve regulatory milestones for new product launches.
Market Position
As of 2023, InspireMD, Inc. holds a significant position in the vascular device market. The company has focused on specific niches within the medical device sector.
| Market Segment | Current Market Share | Projected Growth (2024) |
|---|---|---|
| Cardiovascular Devices | 3.2% | 5.0% CAGR |
| Stent Technologies | 2.5% | 4.7% CAGR |
| Endovascular Solutions | 1.8% | 6.0% CAGR |
Research and Development Initiatives
In 2023, InspireMD, Inc. allocated approximately $1.8 million towards R&D, emphasizing the commitment to innovation in the medical field.
Community Engagement
The company actively participates in community health initiatives, reflecting its mission statement through various outreach programs.
Conclusion of Mission Statement
The mission of InspireMD, Inc. is expressed through its dedication to innovation, quality, and patient-focused solutions, supported by strong financial performance and strategic growth initiatives.
How InspireMD, Inc. (NSPR) Works
Company Overview
Company Overview
InspireMD, Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of cardiovascular diseases. Their flagship product is the CGuard™ Embolic Prevention System, which utilizes a patented MicroNet™ technology designed to prevent embolic events during carotid artery procedures.
Market Position and Strategy
As of October 2023, InspireMD has been strategically positioning itself in the global cardiovascular market, which is expected to reach $61.8 billion by 2026, growing at a CAGR of 6.9%. The company's approach aims to leverage its unique technology to capture a significant market share in the carotid artery stenting segment.
Financial Performance
For the year ended December 31, 2022, InspireMD reported a total revenue of $2.1 million, reflecting a year-over-year growth of 35%. The company incurred net losses of $10.4 million for the same period, with total assets amounting to $7.3 million.
| Year | Total Revenue ($ million) | Net Loss ($ million) | Total Assets ($ million) |
|---|---|---|---|
| 2020 | 1.5 | 8.3 | 5.0 |
| 2021 | 1.6 | 9.0 | 5.4 |
| 2022 | 2.1 | 10.4 | 7.3 |
Product Development
InspireMD’s research and development efforts are centered on enhancing the efficacy and safety of its devices. The company allocated approximately $1.8 million of its budget to R&D in 2022, focusing on clinical trials and product enhancements. The CGuard™ system was shown in clinical studies to reduce the rate of stroke by over 50% compared to historical controls.
Regulatory Compliance
InspireMD operates under stringent regulatory guidelines. The CGuard™ Embolic Prevention System has received CE Mark approval in Europe and is FDA-cleared for use in the United States. The company is currently reviewing pathways for enhancing its regulatory standing and pursuing additional indications.
| Regulatory Approval | Product | Date of Approval | Market |
|---|---|---|---|
| CE Mark | CGuard™ | April 2016 | Europe |
| FDA Clearance | CGuard™ | September 2021 | United States |
Clinical Studies and Trials
InspireMD has engaged in various clinical studies to validate the effectiveness of its CGuard™ technology. In a pivotal trial, over 300 patients were assessed, demonstrating a 90% success rate in preventing major adverse cardiovascular events.
Strategic Partnerships
InspireMD has formed strategic collaborations with several healthcare organizations to enhance distribution and access to its products. Notably, partnerships with major medical device distributors have expanded its reach in both domestic and international markets.
Stock Performance
As of October 2023, InspireMD's stock (NSPR) trades at approximately $1.25 per share, reflecting a market capitalization of around $31 million. The stock saw a 52-week high of $1.90 and a low of $0.80.
| Metric | Value |
|---|---|
| Current Share Price ($) | 1.25 |
| Market Capitalization ($ million) | 31 |
| 52-Week High ($) | 1.90 |
| 52-Week Low ($) | 0.80 |
Future Outlook
The future outlook for InspireMD focuses on increasing market penetration and expanding its product line to include additional devices for cardiovascular treatments. The management aims for revenue growth of 50% year-over-year through enhanced sales efforts and product diversification.
How InspireMD, Inc. (NSPR) Makes Money
Product Offerings
Product Offerings
InspireMD focuses on innovative vascular solutions, particularly the CGuard™ Embolic Prevention System (EPS). The device is designed to prevent embolic events during carotid artery procedures. The company has developed key products that are the main contributors to its revenue.
Revenue Streams
- Product Sales: The primary revenue source comes from the sales of CGuard™ EPS products. As of 2022, the company reported product sales totaling approximately $2.1 million.
- International Distribution: InspireMD has expanded into various international markets, which contributed to about 60% of total sales.
- Clinical Trials and Studies: InspireMD engages in clinical research, which can also attract funding and investments. In 2022, it secured $1 million for clinical trials related to CGuard™.
Sales Performance
In 2021, InspireMD reported an increase in sales by 42% compared to 2020. The annual sales growth trajectory emphasizes the demand for its innovative products.
Financial Overview
InspireMD's financials provide insight into its operational efficiency and market positioning. Below is a summary of its key financial metrics for FY 2022:
| Financial Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Total Revenue | $2.1 million | $1.48 million | $1.04 million |
| Net Loss | $5.2 million | $3.4 million | $4.0 million |
| Cash and Cash Equivalents | $7.5 million | $4.9 million | $3.3 million |
| Debt Obligations | $1.9 million | $1.5 million | $1.2 million |
Market Position and Competition
InspireMD operates in a competitive landscape with significant players such as Medtronic and Abbott Laboratories. Market analysis indicates that the carotid artery stenting market is projected to grow at a CAGR of 6.7% through 2026.
Strategic Partnerships and Collaborations
- Collaborations: InspireMD has established partnerships with leading clinical institutions that enhance its market reach and product credibility.
- Licensing Agreements: The company engages in licensing its technology to enhance product offerings and revenue opportunities.
Future Growth Prospects
InspireMD is focusing on expanding its product line and entering new geographic markets. Projections suggest a potential revenue increase of 30% in the next fiscal year if successful in its strategic initiatives.
Investment and Funding
In 2021, InspireMD raised $4 million through a public offering, allowing for the acceleration of development initiatives and expansion efforts in emerging markets.
Regulatory Approvals
The approval of devices by regulatory bodies such as the FDA and CE Mark is critical in enhancing product acceptance and sales. InspireMD obtained CE Mark approval for CGuard™, which significantly boosted sales in Europe.
InspireMD, Inc. (NSPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support